These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34692470)

  • 1. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
    Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
    Front Oncol; 2021; 11():671972. PubMed ID: 34692470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
    Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
    J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
    Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
    Front Oncol; 2020; 10():411. PubMed ID: 32373508
    [No Abstract]   [Full Text] [Related]  

  • 4. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
    Toms SA; Kim CY; Nicholas G; Ram Z
    J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
    Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
    Front Oncol; 2022; 12():896246. PubMed ID: 35574391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center.
    Chen C; Xu H; Song K; Zhang Y; Zhang J; Wang Y; Sheng X; Chen L; Qin Z
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
    Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
    JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
    Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
    J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
    Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
    J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19).
    Zhu JJ; Goldlust SA; Kleinberg LR; Honnorat J; Oberheim Bush NA; Ram Z
    Discov Oncol; 2022 Oct; 13(1):105. PubMed ID: 36239858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
    Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
    Burri SH; Gondi V; Brown PD; Mehta MP
    Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
    Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
    J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort.
    She L; Gong X; Su L; Liu C
    Front Neurol; 2022; 13():1042888. PubMed ID: 36698900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.
    Mrugala MM; Shi W; Iwomoto F; Lukas RV; Palmer JD; Suh JH; Glas M
    J Neurooncol; 2024 Aug; 169(1):25-38. PubMed ID: 38949692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.